Author:
Meza James M.,Wong Sandra L.
Reference28 articles.
1. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis;Miettinen;Virchows Arch Int J Pathol,2001
2. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033;Blanke;Journal of Clinical Oncology,2008
3. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg;Zalcberg;Eur J Cancer,2005
4. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival;DeMatteo;Ann Surg,2000
5. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors;Dagher;Clin Cancer Res,2002
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献